• Profile
Close

Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis

Osteoporosis International Jan 21, 2019

Solling ASK, et al. – Researchers evaluated 67 postmenopausal women with osteoporosis to determine the consequences of zoledronic acid (ZOL) therapy in this patient population. Odanacatib (ODN), a cathepsin K inhibitor, for treatment of osteoporosis was discontinued due to an increased risk of cardiovascular events. Given the reversible nature of treatment, participants from the LOFT trial were offered treatment with ZOL. They observed an increase in CTX by 107 ± 9%, PINP by 102 ± 16%, osteocalcin by 32 ± 6%, and BSAP by 79 ± 37% between 3 and 12 months, with a rise in BMD at the lumbar spine by 2.8 ± 0.9% from baseline to month 12. However, no significant variation was noted in BMD at the total hip or femoral neck. The investigators also observed a decline in PTH and eGFR levels but an uptick in S-25-hydroxyvitamin D level. Overall, ZOL 5-mg treatment prevented bone loss in women who were previously treated with ODN therapy.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay